Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.38 |
| ▸ | SCN2B | O60939 | 2/20 | 0.38 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831874 | 0.94 | PPARG (0.44) | PPARGCYP2C8SCN9ASCN5ASCN2B | |
| SCHEMBL831954 | 0.93 | CYP2C8 (0.43) | PPARGCYP2C8TACR1KMT2ADDR1 | |
| SCHEMBL831415 | 0.93 | PPARG (0.46) | PPARGCYP2C8SCN9ASCN5ASCN2B | |
| SCHEMBL831952 | 0.92 | PPARG (0.42) | PPARGCYP2C8SCN9ASCN5ASCN2B | |
| SCHEMBL831412 | 0.90 | CYP2C8 (0.41) | PPARGCYP2C8SCN9ASCN5ASCN2B | |
| SCHEMBL831903 | 0.89 | CYP2C8 (0.45) | PPARGCYP2C8SCN9ASCN5ASCN2B | |
| SCHEMBL862206 | 0.89 | CYP2C8 (0.43) | PPARGCYP2C8SCN9ASCN5AKMT2A | |
| SCHEMBL831566 | 0.88 | PPARG (0.43) | PPARGCYP2C8SCN9ASCN5ASCN2B | |
| SCHEMBL832029 | 0.88 | PPARG (0.43) | PPARGCYP2C8SCN9ASCN5ASCN2B | |
| SCHEMBL831532 | 0.88 | CYP2C8 (0.47) | CYP2C8SCN9ASCN5ASCN2BSCN1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | PPARG 4093/4885CYP2C8 847/4885SCN9A 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.